Fueling Innovation. Advancing Discovery. Enabling Breakthroughs.
Announcement Banner
The 2035 Fund is a bold new initiative to power the next generation of life sciences innovation in Massachusetts. Designed to accelerate cutting-edge research through partnerships, foster translation from lab to impact, and close critical infrastructure gaps, this fund will invest in the people, places, and technologies shaping the future of health and science.
The 2035 Fund supports projects that:
The Fund is open to organizations across Massachusetts with a strong vision for driving innovation, collaboration, and inclusive growth in the life sciences.
The 2035 Fund is designed to strengthen every layer of the life sciences ecosystem spanning startups, research labs, industry leaders and the next generation of life sciences talent. By expanding access to incubator space, critical research infrastructure, and funding for scientific projects, the Fund removes barriers to innovation and levels the playing field for emerging and under-resourced sectors. Its focus on translational research, establishing vital resources, and fostering direct collaborations between academia and industry ensures that discoveries are not only made, but meaningfully advanced toward real-world impact. By requiring industry partners to invest in new postdoctoral talent, the Fund also fuels workforce development and builds lasting bridges between scientific research and commercial opportunity.
R.E.D.: Research Equipment Database: Utilize our Research Equipment Database where you can search the equipment that MLSC has funded, all of which is available to external researchers.
D.A.T.A. (Databases, Algorithms, Tools, and Analyses) Repository: Search our D.A.T.A. repository for the datasets, algorithms, and codebases generated with MLSC funds made publicly available.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.